Micardis Related Published Studies
Well-designed clinical trials related to Micardis (Telmisartan)
Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. [2009.09]
Effect of telmisartan on renal outcomes: a randomized trial. [2009.07.07]
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. [2009.07]
Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome. [2009.06.01]
Results of treatment with telmisartan-amlodipine in hypertensive patients. [2009.04]
Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. [2009.04]
Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. [2009.03]
Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication. [2009.02]
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. [2009.01]
Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. [2009.01]
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. [2008.12]
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. [2008.10]
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. [2008.10]
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. [2008.10]
Telmisartan to prevent recurrent stroke and cardiovascular events. [2008.09.18]
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. [2008.08.16]
The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. [2008.06]
Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. [2008.05]
Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. [2008.05]
Telmisartan, ramipril, or both in patients at high risk for vascular events. [2008.04.10]
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events] [2008.04]
[A randomized, double-blind, double-dummy study comparing a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg to telmisartan 80 mg in Chinese hypertensive patients who failed to respond adequately to telmisartan 80 mg] [2008.04]
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. [2008.02]
Nilotinib. [2008]
Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. [2007.12]
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. [2007.12]
Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. [2007.10]
Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke. [2007.09]
Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide. [2007.09]
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). [2007.07]
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. [2007.06]
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. [2007.06]
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. [2007.06]
Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction. [2007.06]
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). [2007]
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. [2007]
The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. [2006.12]
The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. [2006.12]
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. [2006.11]
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. [2006.09]
The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. [2006.09]
Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. [2006.09]
Renal and vascular protective effects of telmisartan in patients with essential hypertension. [2006.08]
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. [2006.01]
Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels. [2006]
The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. [2005.11]
The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. [2005.11]
Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. [2005.07]
The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. [2005.06]
Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. [2005.05]
Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. [2005.04]
Chronobiologically explored effects of Telmisartan. [2005.02]
Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. [2005.02]
The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension. [2004.12]
Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. [2004.12]
A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients. [2004.12]
Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. [2004.12]
Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients. [2004.12]
A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. [2004.12]
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. [2004.10]
Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. [2004.08]
Sustained antihypertensive activity of telmisartan compared with valsartan. [2004.08]
Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. [2004.07]
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. [2004.07]
Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo. [2004.05]
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. [2004.04]
Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. [2004.04]
Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. [2004.01]
The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. [2003.12]
Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers. [2003.12]
Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. [2003.12]
Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. [2003.10]
Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. [2003.08]
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. [2003.06]
Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. [2003.05]
Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. [2003.05]
ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. [2002.11]
Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. [2002.09]
[Evaluation of blood pressure self-monitoring of the residual efficacy of telmisartan compared to perindopril. The EVERESTE study] [2002.07]
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. [2002.07]
Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. [2002.05]
Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. [2002.03]
Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. [2002]
Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. [2001.12]
Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. [2001.11]
Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. [2001.11]
Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 diabetes mellitus. [2001.09]
Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. [2001.06]
Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. [2001.02]
Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. [2001.01]
Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. [2001.01]
Dose response and safety of telmisartan in patients with mild to moderate hypertension. [2000.12]
The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. [2000.12]
Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. [2000.12]
A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. [2000.09]
Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. [2000.07]
ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. [1999.11]
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. [1999.10]
Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. [1999.05]
The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. [1999.04]
|
